Compugen | CGEN - Ebitda


Compugen reported $-9.02M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Arca Biopharma USD -25.07M 5.23M Mar/2025
aTyr Pharma USD -54K 25.9M Mar/2026
Bio Path USD -3.21M 631K Mar/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
Immunic USD -22.78M 753K Jun/2024
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
RedHill Biopharma USD 2.69M 108.46M Jun/2023
TherapeuticsMD USD -1.64M 700K Sep/2023